Provided by Tiger Trade Technology Pte. Ltd.

Design Therapeutics, Inc.

15.68
+0.45002.95%
Post-market: 15.680.00000.00%19:30 EDT
Volume:608.11K
Turnover:9.51M
Market Cap:979.08M
PE:-13.27
High:15.96
Open:15.44
Low:15.27
Close:15.23
52wk High:17.25
52wk Low:4.92
Shares:62.44M
Float Shares:37.01M
Volume Ratio:0.98
T/O Rate:1.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1816
EPS(LYR):-1.2174
ROE:-34.13%
ROA:-22.53%
PB:4.85
PE(LYR):-12.88

Loading ...

Design Therapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
May 05

Oppenheimer Raises Price Target on Design Therapeutics to $21 From $18, Keeps Outperform Rating

MT Newswires Live
·
May 04

Design Therapeutics, Inc. : Oppenheimer Raises Target Price to $21 From $18

THOMSON REUTERS
·
May 04

Oppenheimer Reaffirms Their Buy Rating on Design Therapeutics (DSGN)

TIPRANKS
·
May 04

Analysts Conflicted on These Healthcare Names: Molina Healthcare (MOH), Design Therapeutics (DSGN) and Protagonist Therapeutics (PTGX)

TIPRANKS
·
Apr 29

U.S. RESEARCH ROUNDUP-Coca-Cola Co, Mondelez, Zeta Global Holdings

Reuters
·
Apr 29

Design Therapeutics Inc : Leerink Partners Raises Target Price to $18 From $14

THOMSON REUTERS
·
Apr 29

Design Therapeutics Q1 EPS $(0.29) Beats $(0.34) Estimate

Benzinga Earnings
·
Apr 29

Design Therapeutics Q1 net loss narrows to $17.6 million; R&D expenses fall to $14.4 million

Reuters
·
Apr 29

BRIEF-Design Therapeutics Q1 Basic EPS USD -0.29

Reuters
·
Apr 29

Press Release: Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates

Dow Jones
·
Apr 29

Design Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 24

Design Therapeutics management to meet with Oppenheimer

TIPRANKS
·
Apr 02

Design Therapeutics appoints David Shapiro to board as Class III director

Reuters
·
Apr 02

Design Therapeutics Initiated at Buy by Jefferies

Dow Jones
·
Mar 16

Jefferies Initiates Coverage on Design Therapeutics With Buy Rating, $15 Price Target

MT Newswires Live
·
Mar 16

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics

Reuters
·
Mar 16

Design Therapeutics initiated with a Buy at Jefferies

TIPRANKS
·
Mar 16

Design Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Mar 10

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Design Therapeutics (DSGN) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Mar 10